Related Experiment Videos
Activities of five new fluoroquinolones against Pseudomonas pseudomallei
M D Winton1, E D Everett, S A Dolan
1Division of Infectious Diseases, University of Missouri-Columbia 65212.
Abstract:
Thirty-four isolates of Pseudomonas pseudomallei were tested by a broth microdilution technique for susceptibility to amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin. Ciprofloxacin was the most active agent tested, with an MIC for 90% of the strains tested of 8 micrograms/ml. These in vitro results suggest that the fluoroquinolones tested would not be optimal for therapy of melioidosis.
Insights
This study tested five fluoroquinolones against Pseudomonas pseudomallei. Ciprofloxacin showed the most activity, but results suggest fluoroquinolones are not optimal for treating melioidosis.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Melioidosis is a serious infectious disease caused by *Pseudomonas pseudomallei*.
- Antimicrobial resistance is a growing concern in treating melioidosis.
- Fluoroquinolones are a class of antibiotics with broad-spectrum activity.
Purpose of the Study:
- To evaluate the in vitro susceptibility of *Pseudomonas pseudomallei* isolates to five fluoroquinolone antibiotics.
- To determine the potential role of fluoroquinolones in melioidosis therapy.
Main Methods:
- Broth microdilution technique was used.
- Thirty-four clinical isolates of *Pseudomonas pseudomallei* were tested.
- Susceptibility testing included amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin.
Main Results:
- Ciprofloxacin demonstrated the highest in vitro activity among the tested fluoroquinolones.
- The minimum inhibitory concentration (MIC) for 90% of strains (MIC90) for ciprofloxacin was 8 µg/ml.
- Other tested fluoroquinolones showed less activity.
Conclusions:
- The in vitro activity of the tested fluoroquinolones against *Pseudomonas pseudomallei* suggests they may not be optimal for melioidosis treatment.
- Further research into alternative or combination therapies is warranted.